Tingjian Wang

Tingjian Wang

Auto-generated profile, based on publicly available information

Tingjian Wang

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ADAdam David Durbin
Adam David Durbin
TWTingjian Wang
Tingjian Wang
VWVirangika K. Wimalasena
Virangika K. Wimalasena
MZMark W. Zimmerman
Mark W. Zimmerman
DLDeyao Li
Deyao Li
JQJun Qi
Jun Qi
Gene expression is regulated by promoters and enhancers marked by histone H3 lysine 27 acetylation (H3K27ac), which is established by the paralogous histone acetyltransferases (HAT) EP300 and CBP. These enzymes display overlapping regulatory roles in untransformed cells, but less characterized roles in cancer cells. We demonstrate that the majority of high-risk pediatric neuroblastoma (NB) depends on EP300, whereas CBP has a limited role. EP300 controls enhancer acetylation by interacting with TFAP2β, a transcription factor member of the lineage-defining transcriptional core regulatory circuitry (CRC) in NB. To disrupt EP300, we developed a proteolysis-targeting chimera (PROTAC) compound termed “JQAD1” that selectively targets EP300 for degradation. JQAD1 treatment causes loss of H3K27ac at CRC enhancers and rapid NB apoptosis, with limited toxicity to untransformed cells where CBP may compensate. Furthermore, JQAD1 activity is critically determined by cereblon (CRBN) expression across NB cells. Significance: EP300, but not CBP, controls oncogenic CRC-driven transcription in high-risk NB by binding TFAP2β. We developed JQAD1, a CRBN-dependent PROTAC degrader with preferential activity against EP300 and demonstrated its activity in NB. JQAD1 has limited toxicity to untransformed cells and is effective in vivo in a CRBN-dependent manner. This article is highlighted in the In This Issue feature, p. 587

28 October 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
EPEshini Panditharatna
Eshini Panditharatna
JMJoana G. Marques
Joana G. Marques
TWTingjian Wang
Tingjian Wang
MTMaria C. Trissal
Maria C. Trissal
ILIlon Liu
Ilon Liu
MFMariella G. Filbin
Mariella G. Filbin
Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers that are refractory to standard-of-care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic landscape. To interrogate for epigenetic dependencies, we performed a CRISPR screen and show that patient-derived H3K27M-glioma neurospheres are dependent on core components of the mammalian BAF (SWI/SNF) chromatin remodeling complex. The BAF complex maintains glioma stem cells in a cycling, oligodendrocyte precursor cell–like state, in which genetic perturbation of the BAF catalytic subunit SMARCA4 (BRG1), as well as pharmacologic suppression, opposes proliferation, promotes progression of differentiation along the astrocytic lineage, and improves overall survival of patient-derived xenograft models. In summary, we demonstrate that therapeutic inhibition of the BAF complex has translational potential for children with H3K27M gliomas. Significance: Epigenetic dysregulation is at the core of H3K27M-glioma tumorigenesis. Here, we identify the BRG1–BAF complex as a critical regulator of enhancer and transcription factor landscapes, which maintain H3K27M glioma in their progenitor state, precluding glial differentiation, and establish pharmacologic targeting of the BAF complex as a novel treatment strategy for pediatric H3K27M glioma. See related commentary by Beytagh and Weiss, p. 2730. See related article by Mo et al., p. 2906. This article is highlighted in the In This Issue feature, p. 2711

2 March 2018 in Journal of Oral Pathology & Medicine
Verified
Journal Article
Closed access
PDF file
YWYue Wang
Yue Wang
PWPengfei Wang
Pengfei Wang
OAOleh Andrukhov
Oleh Andrukhov
TWTingjian Wang
Tingjian Wang
SSSiying Song
Siying Song
FZFengqiu Zhang
Fengqiu Zhang

10 April 2021 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
HOHiroto Ohguchi
Hiroto Ohguchi
PPPaul M.C. Park
Paul M.C. Park
TWTingjian Wang
Tingjian Wang
BGBerkley Gryder
Berkley Gryder
DODaisuke Ogiya
Daisuke Ogiya
JQJun Qi
Jun Qi
Lysine demethylase 5A (KDM5A) is a negative regulator of histone H3 lysine 4 trimethy­lation (H3K4me3), a histone mark associated with activate gene transcription. We identify that KDM5A interacts with the P-TEFb complex and cooperates with MYC to control MYC-targeted genes in multiple myeloma cells. We develop a cell-permeable and selective KDM5 inhibitor, JQKD82, that increases H3K4me3 but paradoxically inhibits downstream MYC-driven transcriptional output in vitro and in vivo. Using genetic ablation together with our inhibitor, we establish that KDM5A supports MYC target gene transcription independent of MYC itself by supporting TFIIH (CDK7)- and P-TEFb (CDK9)–mediated phosphorylation of RNAPII. These data identify KDM5A as a unique vulnerability in multiple myeloma functioning through regulation of MYC target gene transcription and establish JQKD82 as a tool compound to block KDM5A function as a potential therapeutic strategy for multiple myeloma. Significance: We delineate the function of KDM5A in activating the MYC-driven transcriptional landscape. We develop a cell-permeable KDM5 inhibitor to define the activating role of KDM5A on MYC target gene expression and implicate the therapeutic potential of this compound in mouse models and multiple myeloma patient samples. See related video from the AACR Annual Meeting 2021: https://vimeo.com/554896826

1 May 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HZHong Zhang
Hong Zhang
TWTingjian Wang
Tingjian Wang
YZYuanyuan Zheng
Yuanyuan Zheng
CYChangxiang Yan
Changxiang Yan
WGWei Gu
Wei Gu
LYLing Ye
Ling Ye

4 April 2023
Verified
Other
Open access
EPEshini Panditharatna
Eshini Panditharatna
JMJoana G. Marques
Joana G. Marques
TWTingjian Wang
Tingjian Wang
MTMaria C. Trissal
Maria C. Trissal
ILIlon Liu
Ilon Liu
MFMariella G. Filbin
Mariella G. Filbin
Supplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma